Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nexavar closer to EU approval for liver cancer indication
According to the company, this positive European Committee for Medicinal Products for Human Use (CHMP) opinion will be elevated to the European Commission where a likely favorable ruling
According to the company, this positive European Committee for Medicinal Products for Human Use (CHMP) opinion will be elevated to the European Commission where a likely favorable ruling
The compound, LXR-623, had been in Phase I testing for the treatment of atherosclerosis. While LXR-623 demonstrated efficacy on biomarkers for atherosclerosis, it had an unfavorable profile for
Data was presented at the 47th annual interscience conference on antimicrobial agents and chemotherapy conference showing that ulifloxacin, the active metabolite of prulifloxacin, Optimer's prodrug antibiotic product candidate,
Results demonstrated that the modified adenovector induced anti-tumor responses and limited expression of TNF in normal tissue. These highly selective adenovectors may provide the basis for a potentially
The system devices advisory panel also recommended the development of additional safety data as a basis for expanding the indicated use to include adult patients. Dr Eli Pines,
Findings show that people with type II diabetes in Europe had insulin initiated at a mean HbA1c of 9.6% and more than 12 months prior to initiation the
The collaboration, which was originally established for a period of two years, has been extended at Bristol-Myers Squibb’s request. Under the terms of the collaboration, the two companies
The double-blind, randomized, placebo-controlled clinical trial – MEND-CABG II – will evaluate the safety and cardioprotective efficacy of its product, MC-1, in patients undergoing coronary artery bypass graft
The 10 selected trials represent the first stage of clinical evaluations of IMC-A12 NCI under a clinical trials agreement between ImClone Systems and the division of cancer treatment
Assuming successful completion of the trial evaluating NV1FGF, Sanofi-Aventis expects to file for marketing approval in 2010. In this study four doses of 4mg each will be administered